Liying Nong, Chen Liao, Jian-Hong Ye, Changwu Wei, Chaiyu Zhao, Weiguaju Nong
The STEAM learning performance and sustainable inquiry behavior of college students in China
Frontiers in psychology
epidermal growth factor receptor egfr t790m mutation standard predictive biomarker thirdgeneration epidermal growth factor receptor tyrosine kinase inhibitor egfrtki treatment t790mpositive patients respond thirdgeneration egfrtkis good prognosis necessitates novel tools supplement egfr genotype detection predicting efficacy stratifying egfrmutant patients various prognoses mixtureofexperts moe designed disassemble large model many small models meanwhile also model ensembling method better capture multiple patterns intrinsic subgroups enrolled patients therefore combination moe cox algorithm potential predict efficacy stratify survival nonsmall cell lung cancer nsclc patients egfr mutations utilized electronic medical record emr pharmacokinetic parameters 326 t790mmutated nsclc patients including 283 patients treated abivertinib phase n177 training ii n106 validation clinical trials additional validation cohort 2 comprising 43 patients treated bpi7711 furthermore 18 patients underwent wholeexome sequencing biological interpretation coxmoe evaluated predictive performance therapeutic response using area curve auc concordance index cindex progressionfree survival pfs coxmoe exhibited aucs 073083 predicting efficacy defined best overall response bor achieved cindex values 064065 pfs prediction training validating cohorts pfs 198 patients low risk median 60 range 10233 months abivertinib treated cohort median 165 range 14274 months bpi7711 treated cohort nonresponder increased 43 hazard ratio hr 056 95 confidence interval ci 040078 p00013 50 hr 0 95 ci 00 p001 compared highrisk median 42 range 1035 months abivertinib treated cohort median 110 range 14251 months bpi7711 treated cohort additionally activated partial thromboplastin time aptt creatinine clearance ccr monocyte steadystate plasma trough concentration utilited construct model found significantly associated drug resistance aggressive tumor pathways robust correlation observed aptt ccr pfs logrank test p001 treatment response wilcoxon test p005 respectively coxmoe offers valuable approach patient selection forecasting therapeutic response pfs utilizing laboratory tests pharmacokinetic parameters setting earlyphase clinical trials simultaneously coxmoe could predict efficacy thirdgeneration egfrtki noninvasively t790mpositive nsclc patients thereby complementing existing egfr genotype detection